Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
“ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to ...
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
Dec 20, 2024 · "ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic...
Vertex Announces US FDA Approval of ALYFTREK - Business Wire
Dec 20, 2024 · Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor
FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for …
Elevated transaminases have been observed in patients treated with Alyftrek. Cases of serious and potentially fatal drug-induced liver injury and liver failure were reported in patients taking a fixed-dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains the same or similar active ingredients as Alyftrek.
Vertex Announces US FDA Approval of ALYFTREK™, a Once
6 days ago · Elevated transaminases have been observed in patients treated with ALYFTREK. Cases of serious and potentially fatal drug-induced liver injury and liver failure were reported in patients taking a fixed-dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains the same or similar active ingredients as ALYFTREK.
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
Dec 20, 2024 · (RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis. Alyftrek is a once-daily ...
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
Dec 20, 2024 · Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of …
Vertex wins FDA nod for once-daily cystic fibrosis triplet
5 days ago · Vertex has priced Alyftrek at a list price of $370,269 per year, which is 7% higher than Trikafta’s annual wholesale acquisition cost of $346,048, according to a securities filing.
Alyftrek Gets FDA Approval for Cystic Fibrosis - Clinical Advisor
2 days ago · Vertex announces US FDA approval of Alyftrek TM, a once-daily next-in-class CTFR modulator for the treatment of cystic fibrosis. News release. Vertex Pharmaceuticals. December 20, 2024.
Vertex Wins FDA Approval for New Cystic Fibrosis Option but
5 days ago · The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid …
- Some results have been removed